The objective of the study was to compare the effectiveness of surfactant treatment either by bolus or surfactant lung lavage followed by inhaled nitric oxide (iNO) therapy in infants with meconium aspiration syndrome (MAS) complicated by persistent pulmonary hypertension (PPHN). In this study, thirteen infants with diagnosis of MAS and PPHN were first treated with conventional respiratory support. Then between 2 and 22 h of life they were randomized either to bolus surfactant treatment (n=6) or surfactant lung lavage (SLL, n=7) treatment. Then all infants were treated with iNO therapy. The groups were compared with regard to their clinical course: changes in PaO 2 , FiO 2 , MAP, OI, A-a oxygen gradient, duration of iNO therapy, length of ventilation and hospitalization. Complications and mortality were also compared. The results showed that infants treated with SLL had significant improvements in oxygenation, decreases in MAP and A-a gradients. But there were no significant differences in duration of ventilation, iNO treatment, length of hospitalization or complications. In conclusion these data show no advantage of SLL therapy over bolus surfactant treatment in infants with MAS complicated by PPHN.
Introduction
Improved perinatal management of meconium aspiration has contributed substantially to a decrease in incidence and mortality because of meconium aspiration syndrome (MAS). In infants not responding to conventional treatment of MAS, other methods such as bolus surfactant, surfactant lung lavage (SLL) as well as extracorporeal membrane oxygenation (ECMO) can be used.
Surfactant treatment by bolus may be associated with inactivation by meconium in the airways, which may explain non-responsiveness in earlier studies. 1 It has been suggested that the administration of surfactant followed by SLL may lead to a washout of residual meconium both mechanically and because of the improved mucocilliary transport of meconium. This approach of treatment may thus lead to a thorough removal of meconium from the respiratory tracts and minimize the damaging effect of meconium on the endogenous surfactant. 1 Another major complication of MAS is the development of persistent pulmonary hypertension (PPHN). Inhaled nitric oxide (iNO) has been used successfully to manage infants with PPHN. The effectiveness of iNO would depend on unimpeded delivery of the gases to the well-ventilated parts of the lungs. It is possible that iNO does not reach the alveoli, which are covered with meconium. Therefore, we hypothesize that SLL will clear the meconium, stabilize the alveoli and increase the diffusion of iNO resulting in better oxygenation.
The objective of the trial
The objective of our trial was to study the effectiveness of the combined therapies of bolus surfactant treatment or SLL followed by iNO in infants with meconium aspiration syndrome complicated by pulmonary hypertension.
Materials
This study was conducted in the neonatal intensive care unit (NICU) of the Neonatology Department of the Poznan University of Medical Sciences, Poznan, Poland. We enrolled 13 neonates into the study during the period between 1998 and 2004. The diagnosis of MAS was based on clinical and radiological criteria. PPHN was diagnosed on the basis of echocardiogram results.
Methodology of the trial
Randomization is shown in the diagram.
Group A1
Group A1 included seven newborns who were treated with a combined therapy (SLL þ bolus surfactant þ iNO). Besides the conventional treatment, SLL with a surfactant solution Survanta was carried out between the 2nd and 22nd hour of life (average time of treatment initiation 9.7±7.4 h). After the lavage treatment, one dose of bolus Survanta at 100 mg of phospholipids per kg of body weight was given.
Subsequently, echocardiogram assessment was carried out for the diagnosis of PPHN; iNO was administered when PPHN was diagnosed. The initial dose of nitric oxide was 20 p.p.m. (Figure 1 ).
Group A2
Group A2 included six newborns treated conventionally. Between the 2nd and 22nd hour of life (average time of treatment initiation 11±6.4 h), the newborns were given one dose of Survanta as a bolus in the amount of 100 mg per kg of body weight. Infants did not undergo SLL. After giving one dose of surfactant as well as conducting an echocardiographic assessment and diagnosing with PPHN, iNO was administered with an initial dose of NO at 20 p.p.m.
Lavage with a surfactant solution. Bronchoalveolar lavage with saline natural surfactant solution was in newborns fulfilling the inclusion criteria, which was carried out after sedation and initial cardiopulmonary stabilization. The steps in surfactant lavage are described below.
(A) Preparation of surfactant solution for lavage 2 1. A natural surfactant Survanta (Ross Abbott Laboratories, Zwolle, The Netherlands) was used. 2. The dose of phospholipids for the lavage solution was 5 mg in 1 ml of physiological salt. 3. The volume of the solution was 15 ml per kg of the patient's body weight. 4. The calculated volume was divided into four parts. 5. A single lavage volume was 2 ml kg À1 .
Example of calculation: If the patient's body weight was 3000 g, 45 ml of surfactant solution was used as a lavage: 9 ml of Survanta supplemented with normal saline up to 45 ml.
(B) Lavage technique 2 Installation of a closed circuit system was used for the administration of lavage. This was possible using a Bodai valve in the connector in the endotracheal tube. The surfactant solution was instilled through the connector, whereas the lung fluid was suctioned through the Bodai valve ( Figure 2 ). This closed lavage and suctioning system helped maintain both mechanical ventilation and positive end-expiratory pressure (PEEP) at constant levels. The prepared volume of the solution was divided into four parts. Lavage and suctioning were conducted in four body positions: on the right and left sides, and in the Trendelenburg and anti-Trendelenburg positions, similar to the administration of the Survanta dose given as treatment (in line with the producer's recommendations). The surfactant solution was administered through the endotracheal tube. After 2 ml of the solution was instilled, the mechanical ventilation was continued. After 3 to 5 respiratory cycles, the secretions were suctioned (Figure 2 ).
Treatment with bolus surfactant. Bolus surfactant was administered through the endotracheal tube after sedation and stabilization. (A) Surfactant preparation A natural surfactant Survanta (Ross Abbott Laboratories) was used.
(B) The technique of surfactant administration
The surfactant was administered endotracheally with a catheter through an intubation tube and through the Bodai valve placed in the connector by the intubation tube. During the application, the mechanical ventilation was continued. The dose of surfactant was 100 mg per kg of body weight. The surfactant was administered in four positions: on the right and left sides, and in the Trendelenburg and anti-Trendelenburg positions. Bolus surfactant was administered once after SLL (group A1) and also once but without SLL prior to it (group A2).
MAS +PPHN

A1-SLL+ BOLUS
A2-BOLUS iNO iNO Figure 1 Scheme of the trial. Figure 2 The surfactant lung lavage (SLL) technique.
Bodai valve
Surfactant solution
Safety of the procedures. During the whole procedure, saturation and heart rate were monitored. Saturation was considered safe if, during lavage, it was within the range of 87 to X93%. If saturation fell below 87%, the parameters of mechanical ventilation were adjusted: peak pressure, fraction of inspired oxygen (FiO 2 ) and frequency of breaths. Lavage or surfactant was not given until saturation reached a safe level. Once this was achieved, the procedure was continued.
Parameters analyzed in the trial
The following parameters were analyzed in both groups:
(1) partial arterial oxygen pressure (PaO 2 ); (2) Fraction of inspired oxygen (FiO 2 ); (3) oxygenation index (OI); (4) alveolar-arterial oxygen gradient (AaDO 2 ).
The parameters listed above were analyzed at six time intervals:
At 15 min before treatment initiation (0 h); after 1 h of combined therapy (1 h); after 2 h of combined therapy (2 h); after 4 h of combined therapy (4 h); after 24 h of combined therapy (24 h); after 48 h of combined therapy (48 h).
The following were also analyzed:
1. length of time on mechanical ventilation; 2. duration of iNO treatment; 3. length of hospital stay; 4. complications; 5. number of deaths.
Equipment. Intermittent mandatory ventilation (IMV) was used as treatment for respiratory failure. Echocardiographic examination was conducted by using HDI 3500 ATL and a trans-receiving head with a frequency of 7 to 4 MHz. iNO was administered by using SLE 3600 INOSYS. The initial and, at the same time, maximum dose of NO was 20 p.p.m. Saturation was measured by using pulse oximeters, and maintained in the range between 87 and 93%. Arterial blood PO 2 and PCO 2 were measured. Biochemical analysis was conducted by using Rapidlab.
Clinical classification and characteristics of recruited newborns. After the diagnosis of MAS, the newborns were divided into two groups: A1 and A2 (Figure 1 ) by randomization. In group A1, infants received bolus surfactant treatment followed by iNO. Group A2 received SLL followed by iNO therapy. There were no statistically significant differences in the following parameters: birth weight, gestational age as well as assessment of clinical condition in the first minutes of life. No statistically significant differences were observed in the frequency of Cesarean section as well as the time for inclusion in the trial. In group A1, the maturity of the newborns was 38.1 (±2.3) weeks of gestation. The average birth weight was 3267 g ( ± 822.4). The overall condition of the newborns in the 1st and 5th minutes of life was assessed according to the Apgar scale. The median in the first minute of life was 5 points and it was 7 points in the fifth minute of life.
In group A2, the maturity of the newborns was 37.8 ( ± 2.1) weeks of gestation. The average birth weight was 3128 g (±1155.4). The overall condition of the newborns in the first and fifth minutes of life was assessed on the basis of Apgar scale. The median in the first minute of life was 4 points and it was 6 points in the fifth minute of life.
Inclusion criteria. The trial was prospective and randomized and included newborns who fulfilled the following criteria:
(1) Gestational ages X35 weeks of gestation; (2) postnatal age p24 h; (3) MAS was diagnosed on the following basis:
presence of meconium-stained amniotic fluid below the vocal cords; clinical symptoms: respiratory failure that required treatment with mechanical ventilation (FiO 2 X40%) to maintain PaO 2 at 50 to 80 mm Hg and saturation of 87 to 93%; radiological findings consistent with MAS.
(4) Parental consent to enter the baby in the study.
Echocardiogram assessment was conducted for the diagnosis of PPHN in all infants diagnosed as MAS. PPHN was diagnosed on the basis of the following echocardiographic parameters: [3] [4] [5] [6] mean pulmonary arterial pressure in the pulmonary trunk X40 mm Hg; ductus arteriosus and foramen ovale; tricuspid valve insufficiency (TI); out of the wave A in M-mode pulmonary valve presentation.
The blood flow in the pulmonary artery was recorded by the Doppler method using a pulse-wave technique and a transreceiving head with a high frequency of ultrasonic beams (7 to 4 MHz). The pressure in the pulmonary trunk was calculated on the basis of the time from the initial blood flow wave until it reached the maximum speed (acceleration time (AcT)). The outflow wave was registered on the way from the right ventricle next to the ring of the pulmonary valve or in the pulmonary trunk. The flow acceleration time is shortened in the pulmonary artery. 3 The mean pressure was calculated on the basis of a mathematical formula: 4 80À(0.5AcT). Mean pulmonary artery pressure (MPAP) <40 mm Hg was defined as the norm.
Randomization. Infants were randomized into groups A1 and A2. Each group of infants was managed by a different group of neonatologists. Throughout the study, the infants stayed in the hospital.
Statistical analysis. Parameters such as PaO 2 , FiO 2 , mean airway pressure (MAP), OI, AaDO 2 as well as duration of hospital stay and the length of time on IMV and iNO were expressed in the interval scale and described with the arithmetic mean value, standard deviation as well as the minimum and maximum values and confidential interval.
The normal distribution of these parameters was checked with Shapiro-Wilk's test. For the parameters that showed normal distribution, the Student's t-test for independent variables was used for comparison of groups A1 and A2; otherwise, non-parametric Mann-Whitney's test was used.
For comparisons of values obtained at 0, 1, 2, 4, 24 and 48 h, once the normal distribution was confirmed, the analysis of variances for repeatable variables was carried out using the post hoc Newman-Keuls test; if normal distribution was not confirmed, the non-parametric Friedman test was used with Dunn's test for repeated comparisons. The Apgar scale as a parameter, expressed in the ordinal number scale, was described with the median as well as the minimum and maximum values. Apgar score between the groups was compared using the non-parametric Mann-Whitney test.
The parameters expressed in the nominal scale, such as the number of deaths and complications, were described with numbers and corresponding percentages. Dependence was tested with Fisher's exact test. Statistical significance of a ¼ 0.05 was assumed for verification of statistical tests.
Statistical calculations were performed using a statistical set StatSoft Inc. (2005), STATISTICA, Tulusa, AZ, USA (data analysis software system), version 7.1.
Results of the trial PaO 2
The mean initial (0 h) PaO 2 before treatment initiation was 48.4 mm Hg (±15.0) in group A1. After 1 h of treatment, an increase to 114.4 mm Hg ( ± 49.8) was observed. After 2 h, the value was 68.1 mm Hg (±15.3), after 4 h 69.6 mm Hg (±19.0), after 24 h 78.7 mm Hg ( ± 18.9) and after 48 h 67.9 mm Hg (±12.3) ( Table 1) .
In group A2, the initial (0 h) oxygen pressure value before treatment was 45.1 mm Hg ( ± 14.3). No increase in this parameter was observed, but after 1 h, its value was 46.7 mm Hg ( ± 14.9). An increase up to 51.1 mm Hg ( ± 19.6) was observed after 2 h, which further increased to 65.5 mm Hg (±38.6) after 4 h and a similar level of 61.9 mm Hg ( ± 18.9) after 24 h and 64.0 mm Hg (±14.0) after 48 h ( Table 2) . A statistically significant increase of PaO 2 in group A1 was observed between 0 and 4 h of treatment (P ¼ 0.0311). The initial values of PaO 2 in groups A1 and A2 did not differ statistically. A comparative analysis of both groups demonstrated that in group A1 the increase in PaO 2 was statistically significantly higher in comparison with group A2 after 1 h of treatment (P ¼ 0.0105). After several hours, the difference was still noted; however, the value was not statistically significant. After 2, 4, 24 and 48 h, there was a smaller difference in the value of PaO 2 in groups A1 and A2 (Figure 3 ).
Fraction of inspired oxygen
The mean value of the initial (0 h) fraction of inspired oxygen before treatment initiation was 95.7% ( ± 11.3) in group A1 and 95.0% (±12.2) in group A2. In group A1, a drop in this parameter to 79.4% ( ± 23.2) was achieved after 1 h, to 67.1% ( ± 20.0) after 2 h, to 57.1% (±16.6) after 4 h, and after 24 h this parameter was maintained at a similar level of 53.7% (±23.2). After 48 h, a drop of FiO 2 to 40.1% ( ± 19.6) was observed (Table 3) .
In group A2, before treatment initiation (0 h) the value of FiO 2 was 95.0% (±12.2), and after 1 h of treatment a drop in this parameter was achieved (to 93.3% ( ± 10.3)), and after 2 h the level was 96.8% (±8.3%). A drop to 89.2% (±15.6) was observed after 4 h, and to 64.0% ( ± 22.2) after 24 h and to 46.0% ( ± 32.3) after 48 h ( Table 4) .
The difference in the initial values of FiO 2 in groups A1 and A2 was not statistically significant. When comparing both groups, it was observed that after the first hour of treatment, the drop of FiO 2 in group A1 was faster than it was in group A2. After several hours, a difference that was statistically insignificant was still noted. In group A1, a drop of FiO 2 was statistically significantly higher than it was in comparison with group A2 after 2 h (P ¼ 0.0130) and after 4 h of treatment (P ¼ 0.0113). After 24 and 48 h, a smaller difference in the value of FiO 2 was observed in groups A1 and A2 (Figure 4 ).
MAP
The initial (0 h) MAP before treatment initiation was 14.3 cm H 2 O ( ± 4.2) in group A1, and 13.8 cm H 2 O ( ± 8.3) in group A2. A drop in this parameter was observed after 1 h of treatment in group A1 to 11.5 cm H 2 O ( ± 3.7) with a further drop in this group after 2 h to 9.8 cm H 2 O (±4.0) and after 4 h to 6.6 cm H 2 O ( ± 5.2). A further drop was observed after 24 h to 4.1 cm H 2 O ( ± 3.6). After 48 h, a further but small increase to 5.0 cm H 2 O (±6.1) was observed (Table 5) .
In group A2, before treatment initiation (0 h), the value of MAP was 13.8 cm H 2 O (±8.28). After 1 h of treatment, no drop in this parameter was observed and it was 13.2 cm H 2 O (±5.0). After 2 h of treatment, a drop to 12.0 cm H 2 O ( ± 5.2) was observed. A further drop was observed after 4 h to 10.9 cm H 2 O ( ± 3.9) and after 24 h to 8.0 cm H 2 O (±3.7). This value decreased to 4.2 cm H 2 O ( ± 2.8) after 48 h ( Table 6) .
The difference between the initial value of MAP in groups A1 and A2 was not statistically significant. When comparing both groups, it was noticed that after the first hour of treatment, the drop in MAP was more rapid in group A1 than in group A2. After 1 and 2 h, the difference was still noted; however, it was statistically insignificant. In group A1, a drop in MAP was statistically significantly higher in comparison with group A2 after 24 h of treatment (P ¼ 0.0423) ( Figure 5) . After 48 h, the values of MAP in groups A1 and A2 were similar. In this group of patients, a drop in MAP that was statistically significant took place between 0 and 24 h of treatment (P ¼ 0.0114). In this group, the drop in MAP during 48 h of treatment was statistically significant between the 1st and 48th hour of treatment (P ¼ 0.0008).
Oxygenation index
The mean initial (0 h) value of the oxygenation index before treatment initiation was 29.8 ( ± 12.5) in group A1 and 32.4 (±25.0) in group A2. In group A1, this value decreased after several hours and was 11.2 ( ± 12.5) after 1 h, 10.0 ( ± 5.5) after 2 h and 6.3 (±6.4) after 4 h. After 24 h, this value decreased to 2.7 ( ± 2.2), and after 48 h to 5.0 ( ± 9.1) ( Table 7) . In group A2, a drop in this parameter was observed after 1 h to 28.8 ( ± 12.1), after 2 h to 26.8 ( ± 19.0), after 4 h to 22.2 ( ± 18.4), after 24 h to 10.4 ( ± 8.1), and after 48 h a drop to 5.7 ( ± 9.1) ( Table 8) .
The difference in the initial value of OI in groups A1 and A2 was not statistically significant. When comparing both groups, it was noted that after 1 h of treatment a drop in OI in group A1 was statistically significantly faster than it was in group A2 (P ¼ 0.0222). In group A1, a drop in OI was also statistically significantly higher when compared with group A2 after 2 h (P ¼ 0.0455), 4 h (P ¼ 0.0455) and 24 h of treatment (P ¼ 0.0423). After 48 h, the values of OI in groups A1 and A2 were similar ( Figure 6 ).
Alveolar-arterial oxygen gradient
The initial values of AaDO 2 before treatment initiation (0 h) were 575.6 mm Hg (±91.0) for group A1 and 589.5 mm Hg (±95.8) for group A2. In group A1, a drop in these values was observed after 1 h of treatment to 423.7 mm Hg (±184.3), after 2 h to A statistically significant drop took place between 0 and 1 h (P ¼ 0.0003), 0 and 4 h (P ¼ 0.0398) and 0 and 48 h of treatment (P ¼ 0.0001). In group A2, a drop in OI between 0 and 48 h of treatment was statistically significant (P ¼ 0.0011).
364.2 mm Hg ( ± 128.8), after 4 h to 305.3 mm Hg ( ± 122.9), after 24 h to 261.0 mm Hg (±160.9), and after 48 h to 178.3 ( ± 144.0). A drop in AaDO 2 during treatment was statistically significant between 0 and 24 h (P ¼ 0.0024) and between 0 and 48 h of treatment (P ¼ 0.0021).
In group A2, after 1 h the value was 575.3 mm Hg (±88.2). After 2 h, an increase to 581.2 mm Hg ( ± 71.2) in this parameter was observed. A drop was noted after 12 h to 506 mm Hg ( ± 112.6), with a further drop after 24 h to 352.3 mm Hg (±177.5) and after 48 h to 226.0 mm Hg (±239.8).
A drop in AaDO 2 during the time of the treatment was statistically significant between 0 and the 48th hour of treatment (P ¼ 0.0017).
The difference between the initial values of AaDO 2 in groups A1 and A2 was not statistically significant. When comparing both groups, it was noted that after 1 h of treatment a drop in AaDO 2 was more rapid in group A1 in than in group A2. Subsequently, the difference was statistically significant (P ¼ 0.0036). After 4 h, a drop of AaDO 2 in group A1 was also statistically significantly higher in comparison with group A2 (P ¼ 0.0106). After 24 and 48 h, a smaller difference was observed between the value of AaDO 2 in groups A1 and A2. These differences were statistically insignificant ( Figure 7) .
Duration of mechanical ventilation
In group A1, the mean time on mechanical ventilation was 6.6 days ( ± 2.6), and in group A2 it was 7.3 days ( ± 1.7). This difference was not statistically significant (P>0.05).
Duration of iNO treatment
The mean duration of iNO treatment was 2.9 days (±1.5) in group A1. In group A2, this value was higher and the duration was 4 days ( ± 1). This difference was not statistically significant (P>0.05).
Length of hospitalization
In group A1, the length of hospitalization was 16.4 days (±5.4) and in group A2 it was 19.8 days ( ± 2.9). This difference was not statistically significant (P>0.05).
Complications
Air leaks. The incidence of pneumothorax was analyzed. In group A1, no cases of pneumothorax were noted. This complication was observed in two newborns from group A2. This value was not statistically significant (P>0.05).
Deaths. There were no deaths in group A1. There were two cases of deaths in group A2. This difference was not statistically significant (P>0.05).
Discussion
Meconium in the airways and alveoli leads to inactivation of endogenously and exogenously replaced surfactant. Therefore, we hypothesized that SLL would improve the clearance of meconium from the airways while replacing the surfactant. 7 Earlier studies on the use of SLL in newborn piglets were published by Paranka et al.
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A solution of Survanta was used for lung lavage. Following this treatment, a rapid improvement in oxygenation was observed. Similar experimental studies on the use of SLL in the treatment of MAS were conducted at different centers by Dargaville et al. 9 and Ogawa and co-workers. [10] [11] [12] The first clinical studies on SLL were conducted by Ogawa 10 and Lam and Yeung. 13 Ogawa administered as a lavage a surfactant solution with a concentration of 12 mg of phospholipids in 1 ml of physiological salt. Earlier, Ohama et al. 11 attempted to prove that a higher concentration is more effective. The volume of the solution was 5 ml per kg of body weight. A significant drop in OI and AaDO 2 was achieved after 4 h of treatment.
Another attempt to define the most optimal dose of surfactant for lavage was undertaken by Chang et al.
14 In group I, the lungs were washed with a surfactant solution with a concentration of 5 mg ml À1 of physiological salt. In group II, lavage was conducted with a surfactant solution with a concentration of 10 mg ml À1 . A significant increase in PaO 2 was observed within 24 h. It was noted that both the first and the second doses of surfactant were effective.
The next phase of study was a multi-center study by Ogawa 10 conducted in 11 centers. A comparative analysis of the group with SLL against the group without SLL demonstrated that a drop in the oxygenation parameter and an increase in the oxygen pressure after 180 min were significantly higher in the SLL group than in the control group. Interesting results of clinical trials were presented by Lam and Yeung. 13, 15 Survanta, a natural surfactant solution with a concentration of 5 mg phospholipids per ml of saline and a quantity of 15 ml per kg of body weight, was administered as a lavage. The results of the trial demonstrated that the average values of OI, MAP, AaDO 2 and FiO 2 were significantly and statistically lower after 48 h of treatment.
Similar trial results were published in 2003 by Maroszyń ska et al. 16, 17 The inclusion criteria used in our study did not differ much from the ones proposed by other researchers. Some of the researchers quoted above considered the level of OI X20 as the only inclusion criterion. 18 In our study, the criteria used were similar to those used by Lam and Yeung. 13, 15 The only difference was in the time for enrollment in the trial, which was extended to 24 h (average time to include newborns transferred from a level II unit). We did not use OI and MAP as the inclusion criteria; only the value of FiO 2 X40% was used.
A more extended time for the inclusion in the studyFup to 120 h was proposed only by Maroszyń ska et al. 16, 17 The majority of the quoted experimental and clinical trials as well as our own study studied the use of natural surfactant solutions in SLL. Earlier, Meister et al. 19 compared the natural and the synthetic surfactants. They proved that there are no statistically significant differences in the results achieved after administrations of either type of surfactant in SLL. Studies on these subjects were also published by Wiswell et al. 20 Their trial was focused on the use of Surfaxin, a new generation synthetic surfactant solution. The trial group comprised 22 newborns and the control group included 15 newborns. The inclusion criteria were similar to the ones quoted above. A statistically significantly faster drop of OI after SLL was observed in comparison with the control group.
The dose of surfactant used for lavage is still a subject for discussion. The smallest dose (8 ml per kg of body weight) of lavage solution was proposed by Wiswell et al. 21 Others have proposed a dose of 10 ml solution per kg of body weight. 9, 14 The most frequently suggested dose is a higher doseFfrom 15 15 to 20 ml kg À1 . 10, 17 In his earlier experimental trials, Ogawa 10 attempted to define the most optimal dose of the lavage solution and he came to the conclusion that a dose of 10 ml kg À1 is most effective.
Similarly, the concentration used in the solution is also a subject of trials. Wiswell et al. 21 proposed the lowest concentration of the drugF2.5 mg ml À1 of physiological salt. . On the other hand, Chang et al. 14 proved that a dose of 5 mg ml À1 is as effective as a dose of 10 mg ml À1 . In our trial, a concentration of 5 mg ml À1 at a dose of 15 ml per kg of body weight was used.
All of the aforementioned clinical trials on the use of SLL in MAS used saline as control groups. None compared bolus treatments with SLL. Meister et al. 19 conducted experimental trials on a rabbit model in which they compared the results of surfactant with bolus surfactant treatment. They also studied the differences in natural and synthetic surfactant treatments. A significant increase in PaO 2 was observed in both natural and synthetic surfactants, SLL, in comparison with groups treated with bolus surfactant and a control group. The increase was observed after 4 h of treatment.
The group of patients with the most severe clinical course of MAS includes cases complicated by PPHN. In the majority of cases, studies on the use of iNO in the treatment of PPHN in term neonates with MAS confirm its effectiveness in oxygenation improvement. 2, 24 It was observed that, 30 min after the administration of NO, there was a visible oxygenation improvement manifested by an increase in PaO 2 and a drop in OI and AaDO 2 .
When conducting independent randomized trials, Chen and Kao observed a significant drop in OI after iNO treatment of PPHN in MAS. Chen et al.
1 noted improvement in 30 min of iNO, whereas Kao et al. observed a statistically significant drop in OI after 60 min of iNO. 25 The effectiveness of iNO in the treatment of PPHN in MAS was also proved by Gupta et al. 26 A clinical trial on the use of iNO in PPHN in MAS was also conducted by Hwang et al. 27 After 1 h of iNO treatment, they observed a statistically significant drop of OI and MAP.
The neonates presented in our study who were diagnosed by an echocardiographic examination with PPHN in the course of a severe MAS, were treated with surfactant prior to the administration of iNO. In this group of patients, the intention was to assess the combined therapy as well as to answer the question whether it was more effective to use SLL followed by bolus surfactant or surfactant only prior to the administration of iNO. The initial dose of NO was 20 p.p.m. The treatment was conducted in the first 24 h of the newborn's life. The average time of treatment initiation was 9.7 ± 7.4 h in group A1 and 11 ± 6.4 h in group A2. Oxygenation, ventilation and other selected clinical parameters were assessed.
Rais-Bachrami et al. 28 attained a faster improvement in oxygenation after surfactant administration followed by iNO. After 20 min, they lowered the dose of NO and after 15 min they stopped the dose of iNO.
The administration of bolus surfactant followed by iNO (group A2) had a positive influence on the improvement in oxygenation. However, in a majority of cases, these results were not statistically significant. An increase in PaO 2 was observed only after 2 h of treatment, and a further increase was noted within 48 h; however, this was not statistically significant. A similar tendency was observed in the values of FiO 2 and OI. Within 48 h, a gradual decrease in these parameters was observed; however, this drop was not statistically significant either. AaDO 2 declined as well. A statistically significant drop was noted after 24 h and then after 48 h of treatment as well as in the time range between the 12th and 24th hour of treatment. A drop in MAP was observed only after 4 h of treatment and a further drop was noted until the 48th hour of treatment; however, this drop was not statistically significant. Substantially better results were observed in cases when, prior to iNO, SLL was used followed by one dose of bolus surfactant.
There is a lack of information regarding the effectiveness of this therapy. Investigators have used solely iNO treatment in severe cases of MAS complicated by PPHN. A drop in OI and an increase in PaO 2 were observed after 30 min, 24 after 60 min 8 and after 24 h of iNO treatment 29 in different studies. In our studies, a significant increase in PaO 2 was observed in the group with SLL after 1 h. In the SLL group, a drop in OI and FiO 2 was statistically significant after 24 and 48 h. When we compared SLL with the group without SLL, we noticed statistically significant differences much sooner, that is, after the first, second and fourth hours.
The drop in AaDO 2 in the SLL group was substantial after 2 and 4 h, with a further drop after 24 and 48 h. MAP also declined significantly in the SLL group after 24 h. However, when comparing the two groups we observed a significant difference only after 48 h. These results are similar to others who did not use SLL but were treated with only iNO. Therefore, we cannot conclude with certainty whether the use of SLL increases the effectiveness of iNO.
Similar to our findings, others did not find statistically significant differences in the length of time on IMV, number of complications and deaths when in comparison with the group that was not treated with iNO. Similarly, in our trial no statistically significant differences were observed in the length of mechanical ventilation and hospitalization. In the group with SLL, bolus surfactant and iNO, as well as no air leaks or deaths, were encountered. In the group with bolus surfactant and iNO, there were 2/6 cases of pneumothorax and 2/6 deaths. However, this difference was not statistically significant. In the first case, pneumothorax was one of the causes of death. In the second case which was complicated by pneumothorax, the patient survived. The other death was due to a sudden stop in heart activity in the course of a severe circulatory failure.
During our study, there was no attempt to answer the important question whether the use of bolus surfactant along with SLL will prevent the development of PPHN and whether it may decrease the need for iNO use. Chang et al.
14 attempted to address this question. They conducted clinical studies on neonates with MAS in whom OI was X20. Prior to iNO use, the airways were washed with a surfactant solution with a concentration of 5 mg ml À1 or 10 mg ml À1 of physiological salt. A statistically significant increase in PaO 2 was observed within 24 h; 5 of 12 neonates required iNO treatment.
Therefore, the results of the trials conducted by researchers quoted in this paper as well as by our own trial indicate that, in severe cases of MAS complicated by PPHN, the administration of bolus surfactant or SLL followed by bolus surfactant prior to iNO treatment improves oxygenation of the patient and may lead to a decrease both in the severity of PPHN and in the duration of iNO treatment. However, no significant decrease in the duration of IMV, hospitalization or in the number of complications and deaths was observed.
Conclusions
(1) The combined therapy: SLL followed by bolus surfactant, in combination with iNO in the treatment of meconium aspiration syndrome accompanied by PPHN, showed significant improvement in oxygenation as well as a decrease in mechanical ventilation parameters. (2) However, SLL followed by bolus surfactant as well as combined therapy: SLL followed by bolus surfactant combined with iNO did not exert significant influence over the duration of mechanical ventilation, iNO treatment as well as the length of hospitalization and the number of complications. (3) On account of small number of the patients, these studies do not have enough power to choose a particular combination of therapies. There is a need for larger series to answer these questions.
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